3-Laser Flow cytometer

在新任命的背景下，我们计划通过几项新的活动来进一步扩大我们的“细胞疗法”计划。我们希望建立临床前研究，并在此研究计划的基础上启动临床I/II期试验。已经存在的GMP实验室基础设施，内科II强大的患者计划和我们完善的GCP研究中心(目前&GT；为了使该计划的翻译研究部分成为可能，以下两个主要研究仪器是强制性的，并因此应用于这一应用：(1)用于生产GMP兼容的细胞疗法的仪器，用于在临床试验中应用于患者，以及封闭系统中的附加电穿孔器(例如，异基因NK细胞，iNKT细胞，CAR-T细胞)和(2)流式细胞仪，用于分析产生的细胞产物和监测免疫细胞及其对免疫系统(免疫监测)和体内肿瘤细胞的影响(例如，包括对最小残留疾病的量化)。在接下来的几年里，这两个主要研究仪器将用于产生细胞产品并执行例如以下临床试验的伴随研究：1.MB-CART-BCMA/CD19在晚期多发性骨髓瘤患者中的I/II期剂量发现和疗效研究“(单中心，单臂，I/II阶段研究，由Tübingen医学院提供的财政支持(AKF方案)，；Pi：B.Besemer/Co-Pi W.Bethge)“MB-CART-CD19/CD22在晚期淋巴系统恶性肿瘤患者中的I/II期剂量发现和疗效研究”(单中心，单臂，I/II期研究，在Tübingen医学院申请财政支持(AKF计划，PI：W.Bethge/Co-PI C.Lengerke))。“自然杀伤细胞免疫疗法与PARP抑制相结合以克服急性髓系白血病中NKG2D介导的免疫逃避”(NAKIP-AML；三中心I/II期研究，Pi Tübingen：Claudia Lengerke；Tübingen und Dresden：同种异体NK细胞制造中心；该研究基于Lengerke教授研究小组产生的临床前数据，见Paczulla，...，Lengerke。《自然》，2019年；研究已获得国家CT的资助)4.类似于(3)关于高危AML异基因移植后的巩固(研究在准备中，PI：C.Lengerke/Co-PI：D.Schneidaind)5.iNKT细胞和关于移植物抗宿主病和其他免疫性疾病的其他细胞疗法(研究方案，PI：D.Schneidaind/Co-PI：R.Haraszti)

In the context of a new appointment we plan to further expand our “Cell Therapy” program by several new activities. We wish to build preclinical research and initiate, based on this research program, clinical phase I/II trials. The already existing GMP lab infrastructures, the robust patient programs of the Internal Medicine II and our well-established GCP Study Center (currently >60 active clinical trials and 300 patients/year) will provide substantial support to establish this translational research program.To enable the translational research part of the program, following two Major Research Instruments are mandatory and thus applied for in this application:(1) an instrument for GMP-compliant production of cell therapies for application in patient in clinical trials, with an additional electroporator in closed system (e.g., allogeneic NK cells, iNKT cells, CAR-T cells) and(2) a flow cytometer for the analysis of the produced cellular products and the monitoring of the immune cells and their effect on the immune system (immunomonitoring) as well as on the tumor cells in vivo (e.g., including quantification of the minimal residual disease).Within the next years, both Major Research Instrument will be used to generate cellular products and to perform the accompanying research for example for the following clinical trials:1. „A phase I/II dose finding and efficacy study of MB-CART-BCMA/CD19 in patients with advanced multiple myeloma“ (single-center, single-arm, phase I/II study, financial support awarded by the Medical Faculty Tübingen (AKF program), ; PI: B. Besemer/ Co-PI W. Bethge).2. “A phase I/II dose finding and efficacy study of MB-CART-CD19/CD22 in patients with advanced lymphoid malignancies” (single-center, single-arm, phase I/II study, financial support applied for at the Medical Faculty Tübingen (AKF program), PI: W. Bethge/ Co-PI C. Lengerke).3. „Natural Killer Cell Immunotherapy in combination with PARP-inhibition to overcome NKG2D-mediated immune evasion in Acute Myeloid Leukemia“ (NAKIP-AML; triple-center phase I/II study, PI Tübingen: Claudia Lengerke; Tübingen und Dresden: manufacturing centers for allogeneic NK cells; the study is based on pre-clinical data generated in the research group of Prof. Lengerke, see Paczulla,..., Lengerke. Nature, 2019; study has been awarded funding by the NCT)4. Similar as in (3) for consolidation after allogeneic transplantation at high risk AML (study in preparation, PI: C. Lengerke/ Co-PI: D. Schneidawind)5. iNKT cells and additional cellular therapies concerning graft-versus-host disease and other immunological diseases (study protocol in preparation, PI: D. Schneidawind/Co-PI: R. Haraszti)